Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BXQ-350 in advanced solid tumors and recurrent high-grade gliomas
NCT02859857Phase 1Completed
- Sponsor
- Bexion Pharmaceuticals
- Start
- Sep 2016
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of BXQ-350 in solid tumor (advanced stage), glioma, ependymoma and 1 more (6 arms), sponsored by Bexion Pharmaceuticals. Primary endpoints: Maximum Tolerated Dose at 12 months, Objective Response Rate per RECIST 1.1 at 12 months and 1 more. Started Sep 2016; status: completed.
02
Drugs
BXQ-350
03
Conditions
solid tumor (advanced stage)gliomaependymomagastrointestinal tumor
Beyond the preview
Go deeper on NCT02859857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02859857.